Deep venous thrombosis annually affects 1 of 1000 individuals (1 ) , causing severe morbidity and potentially lethal pulmonary embolism (1 ) . Together, deep venous thrombosis and pulmonary embolism constitute venous thromboembolism, the risk of which is increased in patients with rheumatoid arthritis and other autoimmune disorders (2) (3) (4) (5) (6) (7) . A possible mechanism may relate to the increased inflammation characteristic of these diseases, but the exact etiology is unknown (8 ) .
Rheumatoid factor is an autoantibody directed against the Fc-region of IgG, and measurements of rheumatoid factor are currently used in the classification of rheumatoid arthritis (9 ) . Increased concentrations of rheumatoid factor are present in approximately 70% of patients with rheumatoid arthritis (10 ) and 1%-16% of individuals in the general population (11) (12) (13) (14) . In patients with rheumatoid arthritis, increased rheumatoid factor is associated with markers of inflammation and disease activity (15 ) . It is presently unknown if increased concentrations of rheumatoid factor is associated with risk of venous thromboembolism.
We tested the hypothesis that increased concentrations of rheumatoid factor are associated with increased risk of deep venous thrombosis in individuals without autoimmune rheumatic disease in the general population. For this purpose, we measured baseline plasma concentrations of IgM rheumatoid factor in 54 628 Danish individuals and followed them for up to 32 years.
Methods

STUDY POPULATION
The study was approved by Herlev Hospital, Copenhagen University Hospital, and Danish ethics committees and was conducted according the Declaration of Helsinki. Written informed consent was provided by all participants, each only appearing in 1 of the 2 studies.
THE COPENHAGEN CITY HEART STUDY
The Copenhagen City Heart Study is a prospective study of the Copenhagen general population initiated in 1976 (16 ) . Participants were selected randomly from the national Civil Registration System to represent the Danish population aged 20 -100 years. All participants were white and of Danish descent, as documented through ethnicity information in the Danish Central Population Register, which covers all people living in Denmark. Data were obtained from blood samples, a physical examination, and a self-administered questionnaire that was reviewed with an investigator on the day of attendance. Of 9752 participants from the 1981-83 examination of the cohort, we excluded 44 individuals with autoimmune rheumatic disease (see Supplemental Table 1 , which accompanies the online version of this article at http://www.clinchem.org/content/vol61/issue2) and 51 with venous thromboembolism before blood sampling, leaving 9657 participants for analyses.
THE COPENHAGEN GENERAL POPULATION STUDY
The Copenhagen General Population Study is a prospective study of the Danish general population initiated in 2003 (16 ) . Participants were recruited and examined as in the Copenhagen City Heart Study. Of 46 620 participants examined in 2004 -12, we excluded 534 with autoimmune rheumatic disease and 1115 with venous thromboembolism before blood sampling, leaving 44 971 participants for analyses.
DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM
We followed all individuals from the day of examination until the occurrence of deep venous thrombosis, pulmonary embolism, death (n ϭ 7988), emigration (n ϭ 167), or autoimmune rheumatic disease (n ϭ 432), whichever came first. There were no losses to follow-up. Information on dates and diagnoses from all clinical hospital departments in Denmark (including emergency departments and outpatients from 1995 onward, but not from general practitioners) were obtained from the 2 (17 ) . This approach has previously been described by us and others (17, 18 ) and was recently validated against chart review with a positive predictive value of 59% for venous thromboembolism diagnosed in any setting and 75% for venous thromboembolism diagnosed during inpatient admission (19 ) .
RHEUMATOID FACTOR
Plasma IgM rheumatoid factor was measured by use of turbidimetry (Konelab). Plasma samples from The Copenhagen City Heart Study (n ϭ 9657) were drawn in 1981-83 and frozen at Ϫ20°C until measurement in 2009 -10. Some plasma samples (n ϭ 12 211) from the Copenhagen General Population Study were drawn in 2004 -06 and frozen at Ϫ80°C until measurement in 2009 -10. Additional samples (n ϭ 32 760) were drawn in 2008 -12 and measured fresh immediately after sampling. Investigators were blinded to venous thromboembolism diagnoses when measuring rheumatoid factor, and vice versa.
COVARIATES
Tobacco smoking was recorded as the daily number of cigarettes or equivalent smoked (1 cigarette ϭ 1 g tobacco) at examination, together with pack-years of cumulative smoking (1 pack-year ϭ 20 cigarettes or equivalent smoked daily for 1 year). We also recorded the use of oral contraceptives among premenopausal women, hormone replacement therapy among postmenopausal women, marital status (single, married, separated, divorced, or widowed), level of education (elementary 1-9 years of education, high school 10 -12 years, or academic Ͼ12 years), and leisure time physical activity (Ͻ2 h per week, 2-4 h of light exercise per week, 2-4 h of demanding exercise per week, or Ͼ4 h of exercise per week). Body mass index was measured weight in kilograms divided by measured height in meters squared. Plasma concentrations of total cholesterol, HDL cholesterol, LDL cholesterol, and high-sensitivity C-reactive protein were measured by use of standard hospital assays (Boehringer Mannheim or Konelab). Genotyping for factor V Leiden R506Q (rs6025) and prothrombin G20210A (rs1799963) was done as reported previously (20, 21 ) . Information on age and sex were 100% complete, whereas information on other covariates were Ͼ97% complete.
Finally, we obtained information from the national Danish Patient Registry and the Danish Cancer Registry on hospital admissions (and outpatient contacts from 1995 onward), on major surgery requiring general anesthesia, on pregnancy, on cancer diagnoses, and on autoimmune rheumatic disease diagnoses.
STATISTICAL ANALYSIS
We used STATA 13.1. We corrected the frozen rheumatoid factor concentrations to fresh concentrations according to percentiles of the distribution for fresh and frozen samples; importantly, however, if uncorrected values were used, results were similar to those reported.
First, the association between rheumatoid factor and the risk of deep venous thrombosis was studied on a continuous scale of doublings of rheumatoid factor as the predictor variable. Second, the association was investigated by comparing individuals by categories of rheumatoid factor. To select optimal cutpoint values for categories of rheumatoid factor in explorative analyses, we plotted the hazard ratios for deep venous thrombosis dependent on different cutpoint values of rheumatoid factor, ranging from 10 to 120 IU/mL (Fig. 1) . We then chose the lowest threshold that resulted in a significant association between rheumatoid factor and deep venous thrombosis and constructed the categories by doublings from this value, resulting in the following groups: Ͻ15, 15-29, 30 -59, 60 -119, and Ն120 IU/ mL. Additional plots were constructed by use of right truncation at 1 and 5 years of follow-up. Third, to examine local behavior, the association between rheumatoid factor and risk of deep venous thrombosis was examined by use of a multivariable adjusted restricted cubic spline model with 3 knots and use of Cox regression calculated on logarithmic values of rheumatoid factor in the range of 10 -120.
Hazard ratios with 95% CIs were calculated by use of Cox proportional hazard regression models with age as time scale and delayed entry at examination; corresponding subhazard ratios were calculated by use of Fine-Gray models. Multivariable models were adjusted for known risk factors for venous thromboembolism and markers of lifestyle and social status at study entry, that is, for age, sex, body mass index, current daily tobacco use, cumulative tobacco consumption, current smoking, use of oral contraceptives and hormone replacement therapy, marital status, length of education, leisure time physical activity, total cholesterol, HDL cholesterol, LDL cholesterol, and systolic blood pressure, as well as for any cancer 1 year before or after an event (see online Supplemental Table 2), hospitalization within 3 months before an event, and major surgery within 3 months before an event. Only 1 deep venous thrombosis event was related to pregnancy or the postpartum period, and thus we did not adjust for this. Missing covariate values were imputed by use of multivariable normal regression imputation; however, results were similar when imputed values were not used. Individuals were censored at emigration, diagnosis of any autoimmune rheumatic disease, end of follow-up (April 10, 2013), deep venous thrombosis, or pulmonary embolism, whichever came first. In Cox regression models, death also led to censoring, whereas in Fine-Gray regression models death acted as a competing event. Cumulative incidences were plotted with the use of Kaplan-Meier and Fine-Gray methods. For trend tests, groups of individuals were classified as 1-5 according to increasing rheumatoid factor concentrations. In Cox proportional regression analyses, the assumption of proportional hazards was tested graphically, and no violations were observed.
Sensitivity analyses were performed after adjustment by use of time-varying covariates obtained in the Copenhagen City Heart Study in 1991-94 and 2001-03, after further adjusting for C-reactive protein, factor V Leiden R506Q, and prothrombin G20210A, and after excluding individuals with frozen rheumatoid factor samples, any missing lifestyle covariates, comorbidity at baseline, and individuals ever developing autoimmune rheumatic disease. We also assessed the risk of unprovoked deep venous thrombosis and calculated stratum-specific hazard ratios of deep venous thrombosis by performing subgroup analyses according to sex, age, body mass index, smoking status, C-reactive protein concentrations, and study cohort. For this purpose, we chose a rheumatoid factor cutpoint concentration of 38 IU/mL, corresponding to the upper limit of the reference interval (9 ). The upper limit of the reference interval was the 2.5% highest concentration of rheumatoid factor, before exclusion of individuals with autoimmune rheumatic disease. Tests for interaction were performed by introducing a 2-factor interaction term in Cox models.
Absolute 5-year risks of deep venous thrombosis (percentages) were estimated by use of Poisson regression models, stratified by categories of rheumatoid factor, age, sex, and obesity (body mass index Ն30 kg/m 2 ).
Results
During 368 381 person-years of follow-up, 670 participants developed deep venous thrombosis and 539 developed pulmonary embolism. Baseline characteristics of the 54 628 study participants are shown in Table 1 .
DEEP VENOUS THROMBOSIS Fig. 1 , A-C, shows the multivariable adjusted hazard ratios of deep venous thrombosis comparing individuals with a rheumatoid factor concentration greater than or (D-F), Restricted cubic spline plot of the association between rheumatoid factor concentration and risk of deep venous thrombosis. Hazard ratios (HRs) with 95% CIs were multivariable adjusted. Risk of deep venous thrombosis within 1 year from study entry (upper panels), within 5 years from study entry (middle panels), and in entire follow-up period (lower panels). On the basis of 54 628 individuals from the general population. equal to a cutpoint vs below, as a function of different cutpoint values, and for 3 different durations of follow-up. A rheumatoid factor concentration Ն vs Ͻ100 IU/mL showed the strongest association with deep venous thrombosis, with multivariable adjusted hazard ratios of 9.0 (95% CI 3.1-26) for 1-year follow-up, 4.3 (2.2-8.5) for 5-year follow-up, and 3.1 (1.7-5.6) for up to 32 years of (mean 6.7-year) follow-up. Fig. 1 , D-F, shows the multivariable adjusted hazard ratios calculated by use of restricted cubic splines for the 3 durations of follow-up.
The cumulative incidences of deep venous thrombosis as a function of age by 5 categories of rheumatoid factor concentrations are shown in Fig. 2 (log-rank trend P ϭ 6 ϫ 10 Ϫ6 ). During maximal follow-up, the multivariable adjusted hazard ratios for deep venous thrombosis vs rheumatoid factor concentrations Ͻ15 IU/mL were 1.3 (95% CI 1.0 -1.5) for 15-29 IU/mL, 1.7 (1.0 -2.8) for 30 -59 IU/mL, 2.4 (1.3-4.3) for 60 -119 IU/mL, and 3.0 (1.6 -5.6) for Ն120 IU/mL (trend P ϭ 6 ϫ 10 Ϫ7 ) (Fig. 3) . On the basis of 54 628 individuals from the general population.
SENSITIVITY ANALYSES
Similar results were observed when the 2 cohorts were analyzed separately (see online Supplemental Fig. 1) ; when time-varying covariates were used for multivariable adjustment in the Copenhagen City Heart Study (see online Supplemental Fig. 2 ); when the multivariable adjusted model was further adjusted for C-reactive protein or factor V Leiden and prothrombin mutations (see online Supplemental Figs. 3 and 4); and when analyses were restricted to participants with fresh blood samples and participants without missing covariates, comorbidities at baseline, or autoimmune rheumatic disease (see online Supplemental Figs. 5-8). Also, results were similar when only unprovoked deep venous thrombosis was assessed and when risks were calculated by use of Fine-Gray regression (see online Supplemental Figs. 9 and 10). In strata by sex, age, body mass index, current smoking status, and study cohort, the association between a positive rheumatoid factor status (Ͼ38 IU/mL) and increased risk of deep venous thrombosis was significant (Fig. 4) . However, in participants with C-reactive protein Ͼ3 mg/L, the 95% CI for the hazard ratio overlapped 1.0, but there was no evidence of interaction in this or any other analyzed strata.
PULMONARY EMBOLISM AND ANY VENOUS THROMBOEMBOLISM
Compared with rheumatoid factor concentrations Ͻ15 IU/mL, the multivariable adjusted hazard ratios for pulmonary embolism during maximum of follow-up were 0.9 (0.7-1.2) for 15-29 IU/mL, 1.5 (0.9 -2.5) for 30 -59 IU/mL, 1.3 (0.6 -3.0) for 60 -119 IU/mL, and 1.9 (0.8 -4.2) for Ն120 IU/mL (trend P ϭ 0.19) (Fig. 3) . The corresponding values for any venous thromboembolism were 1. 
Pulmonary embolism
Rheumatoid factor (IU/mL) 444 14. 
Any venous thromboembolism
Rheumatoid factor (IU/mL) 876 28. On the basis of 54 628 individuals from the general population. P values are for trend across categories of rheumatoid factor concentrations. HR, hazard ratio.
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ABSOLUTE RISK OF DEEP VENOUS THROMBOSIS
The highest absolute 5-year risks of deep venous thrombosis of 10% and 8% were seen in obese men and women age Ͼ60 years, with rheumatoid factor concentrations of Ն120 IU/mL (Fig. 5) ; corresponding risks in individuals with a rheumatoid factor concentration Ͻ15 were 2.2% and 1.6%.
Discussion
Our principal novel finding is that individuals from the general population with increased concentrations of rheumatoid factor had up to 3-fold increased long-term risk and up to 9-fold increased 1-year risk of deep venous thrombosis.
Mechanistically, the present findings may be understood as follows. It is well recognized that increased rheumatoid factor serves as a marker of disease activity and inflammation in patients with rheumatoid arthritis, as it is associated with increased concentrations of acute-phase reactants (15 ) , disease progression (22, 23 ) , extraarticular manifestations (24 -26 ) , and cardiovascular disease (27) (28) (29) . Thus, as systemic inflammation has been linked to development of venous thromboembolism (30 -32 ) , increased inflammation in patients with increased rheumatoid factor and/or rheumatoid arthritis is likely to contribute to the increased incidence of venous thromboembolism (2, 8 ) . Indeed, our observations of a positive association between increased rheumatoid factor and C-reactive protein at baseline suggest that rheumatoid factor correlates with low-grade inflammation in nonrheumatic individuals, which could explain our findings. However, we also found the association between increased concentrations of rheumatoid factor and increased risk of deep venous thrombosis to be significant in individuals without even low-grade inflammation. It is thus possible that rheumatoid factor serves as a marker of inflammation and immune activity independent of C-reactive protein. An alternative explanation is that rheumatoid factor even in the absence of systemic inflammation, through endothelial injury, directly mediates deep venous thrombosis. Indeed, it has previously been proposed that rheumatoid factor through immune complex formation plays a direct pathogenic role in endothelial damage and cardiovascular disease (33, 34 ) , and several studies have found an independent association Hazard ratios (HRs) with 95% CIs were multivariable adjusted. CCHS, Copenhagen City Heart Study; CGPS, Copenhagen General Population Study.
‡ Measurements of C-reactive protein were available only in the Copenhagen General Population Study.
between increased rheumatoid factor and endothelial dysfunction in rheumatic patients (33, 35, 36 ) . Taken together, these data thus suggest the possibility that increased rheumatoid factor concentrations-either through lowgrade inflammation or through endothelial damage-lead to increased risk of deep venous thrombosis. Our findings regarding the relationship between increased rheumatoid factor and pulmonary embolism are less clear. This discrepancy may be attributed to the fewer events of pulmonary embolisms in our cohort. An alternative explanation is that rheumatoid factor is associated differentially with deep venous thrombosis and pulmonary embolism, as has been observed with other risk factors for venous thromboembolism (37) (38) (39) (40) .
Major strengths of our study include the prospective population-based design comprising a large cohort of the general population, the large number of events, and the long observation period with no losses to follow-up. Moreover, the association between increased rheumatoid factor and increased risk of deep venous thrombosis was consistent within 2 separate studies and in all sensitivity analyses, including all analyzed strata.
Potential study limitations include selection bias; however, owing to the recruitment of study participants from the general population without knowledge of rheumatoid factor concentration or disease status, selection bias is unlikely to explain our findings. Another potential limitation is diagnostic misclassification, where some patients with deep venous thrombosis and pulmonary embolism may not have been treated at hospitals or treated as outpatients before the inclusion of outpatients in the Danish Patient Registry in 1995. However, when analyzing the 2 cohorts separately, the association between rheumatoid factor and deep venous thrombosis is also evident in the Copenhagen General Population study, which was initiated after outpatient visits were included in the Danish Patient Registry. Misclassification of autoimmune rheumatic diseases is also possible, as some individuals may go undiagnosed or receive care in general practice. This would tend to overestimate our findings, since individuals with autoimmune rheumatic disease are at increased risk of developing venous thromboembolism (5-7 ) . However, as adjustment for physical activity and concentrations of C-reactive protein did not attenuate the association, misclassification of autoimmune rheumatic diagnoses are unlikely to largely affect our findings. Moreover, our risk estimates of deep ve- On the basis of 54 628 individuals from the general population.
nous thrombosis exceed the risk increase reported in patients with autoimmune rheumatic disease (5, 6 ) . Further, potential residual confounding cannot be ruled out, as we were not able to adjust for confounding illnesses treated in general practice or for any use of medication. Increasing concentrations of rheumatoid factor were associated with poor health conditions at baseline, that is, older age, heavier cumulative smoking history, higher systolic blood pressure, and higher concentrations of C-reactive protein. Nevertheless, this is unlikely to fully explain our findings, since these parameters and other major risk factors for deep venous thrombosis were included in our multivariable models, and further exclusion of individuals with comorbidity at baseline gave similar results. Finally, as we studied only white people of Danish descent, our findings may not necessarily apply to other races; however, we are not aware of data to suggest that the present findings should not be applicable to most races.
Our categorization of rheumatoid factor concentrations also deserves a comment. Due to lack of consensus cutpoint values for rheumatoid factor in a general population setting, we examined different cutpoint values, thereby also exploring the robustness of the associations. We selected the lowest cutpoint value revealing a significant association between rheumatoid factor and deep venous thrombosis, thereby including almost 17% of the study population in the rheumatoid factor-positive groups. The high prevalence of individuals with a positive rheumatoid factor, and thus at increased risk of deep venous thrombosis, emphasizes the impact of our findings in the general population. However, these findings need to be confirmed in another population before being considered for clinical use.
In conclusion, increased rheumatoid factor in the general population was associated with up to 3-fold increased long-term risk and up to 9-fold increased 1-year risk of deep venous thrombosis. This suggests that severely increased rheumatoid factor could be considered as a thrombophilic condition.
